Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaBay Pharmaceuticals has completed dosing of the first cohort of volunteers in a multi-cohort Phase I safety study of a bladder and catheter lavage solution of NVC-422, the company's lead aganocide compound.
Subscribe to our email newsletter
This clinical program is aimed at preventing the development of catheter associated urinary tract infections (CAUTI).
Behzad Khosrovi, vice president of R&D at NovaBay, said: “The CAUTI program is NovaBay’s second clinical development program focused on reducing the problems of infections in hospitals. Our other internal program is progressing in early Phase II studies, to reduce the threat of infections to patients caused by Staph. aureus. We look forward to continuing the rapid advancement of these programs through their clinical development.”